Gernert Michael, Tony Hans-Peter, Schwaneck Eva Christina, Fröhlich Matthias, Schmalzing Marc
Department of Medicine II, Rheumatology and Clinical Immunology, University Hospital of Würzburg, Oberdürrbacher Str. 6, 97080, Würzburg, Germany.
Arthritis Res Ther. 2020 Aug 8;22(1):183. doi: 10.1186/s13075-020-02255-3.
Autologous hematopoietic stem cell transplantation (aHSCT) is a treatment option for a selected group of systemic sclerosis (SSc) patients with good available evidence but can be associated with considerable morbidity and mortality. The aim of this study was to describe infectious complications and distinct immune reconstitution patterns after aHSCT and to detect risk factors in lymphocyte subsets, which are associated with an elevated rate of infections after aHSCT.
Seventeen patients with SSc were included in this single-center retrospective cohort study. Clinical and laboratory data was collected before and for 12 months after aHSCT, including immunophenotyping of peripheral whole blood by fluorescence-activated cell sorting.
Cytomegalovirus (CMV) reactivations were common in CMV-IgG-positive patients (50%) and needed treatment. Mycotic infections occurred in 17.6%. One patient died (resulting in a mortality of 5.9%) due to pneumonia with consecutive sepsis. All patients showed decreased T helper cells (CD3/CD4) and within the B cell compartment decreased post-switched memory B cells (CD19/CD27/IgD) and elevated naïve B cells (CD19/CD27/IgD) until 12 months after aHSCT. Patients who developed infections had significantly lower B cells before aHSCT than patients who did not develop infections.
After aHSCT, monitoring for infectious complications, especially for CMV reactivations, is crucial as the reconstitution of the immune system takes longer than 12 months. Low peripheral B cells might be a risk factor for an elevated infection rate.
自体造血干细胞移植(aHSCT)是部分系统性硬化症(SSc)患者的一种治疗选择,有充分的证据支持,但可能伴有相当高的发病率和死亡率。本研究的目的是描述aHSCT后的感染并发症和独特的免疫重建模式,并检测淋巴细胞亚群中与aHSCT后感染率升高相关的危险因素。
本单中心回顾性队列研究纳入了17例SSc患者。收集aHSCT前及术后12个月的临床和实验室数据,包括通过荧光激活细胞分选对外周全血进行免疫表型分析。
巨细胞病毒(CMV)再激活在CMV-IgG阳性患者中很常见(50%),需要治疗。真菌感染发生率为17.6%。1例患者因肺炎并发败血症死亡(死亡率为5.9%)。所有患者的辅助性T细胞(CD3/CD4)均减少,在B细胞亚群中,转换后记忆B细胞(CD19/CD27/IgD)减少,而初始B细胞(CD19/CD27/IgD)在aHSCT后12个月内升高。发生感染的患者在aHSCT前的B细胞水平显著低于未发生感染的患者。
aHSCT后,由于免疫系统重建时间超过12个月,监测感染并发症,尤其是CMV再激活至关重要。外周血B细胞水平低可能是感染率升高的一个危险因素。